Menu
Recruiting NCT05875103

The Links Between Executive and Linguistic Processes and Their Lesional Determinants From a Verbal Fluency Task

No phase Interventional Cognitive Neurodegenerative Stroke Verbal Fluency Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: linguistic processes.
Who it may be relevant to
Registry conditions: Cognitive Neurodegenerative, Stroke, Verbal Fluency Disorders. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Verbal fluency test require to produce as much words as possible in one or two minutes. This test is highly sensitive to main brain diseases and are therefore widely used in clinical routine for diagnostic purpose. The verbal fluency task requires several cognitive processes including executive and linguistic processes for which it is difficult to extract the origin of the deficit. For this reason, fluency tests are variably interpreted in terms of executive or language. The implementation of an experimental protocol exploring each of these processes separately and studying the links between the verbal fluency task and each of these processes should allow a better understanding of the origin of the verbal fluency deficit after brain injury and improve the identification of key brain structures. Indeed, the lesion determinants of this task remain to be clarified despite remarkable advances due to the evolution of imaging techniques (voxel-based lesion-symptom mapping (VLSM); voxel-based morphometry (VBM)). Furthermore, while the direct assessment of linguistic process, semantic memory, and processing speed is well defined, the examination of the executive component (i.e., strategic search process) remains unsettled and will be undertaken in this study. This work will take advantage of data from previous multicenter work, validated methodologies for both analysis and interpretation of cognitive performance as well as anatomic-clinical correlations at the voxel level and will be performed in cognitive neurodegenerative and cerebrovascular disease.

Interventions

  • Diagnostic test linguistic processes
    Linguistic processes are assessed by performance score on the following tests: * naming tests : BNT 34 (Colombo \& Assal, 1992) and semantic naming adapted from the BECS-GRECO (Merck et al., 2011) * vocabulary test (Mill Hill - Deltour, 1993), * repetition tests (Gremots - Bézy et al., 2016), * articulatory speed (Majerus, 2014 ; Roussel et al., 2012) * semantic matching task adapted from the PPT (Howard \& Patterson, 1992) and from the BECS-GRECO (Merck et al., 2011), * semantic categorization

Primary outcome measures

  • Corelation between Linguistic test performance score and verbal fluency score [Time frame: 1 hour]

Eligibility criteria

Inclusion criteria

  • For Cognitive cortical neurodegenerative diseases PATIENTS
  • informed consentPatients between 40 and 85 years old,
  • French native language,
  • Social Security affiliation,
  • Can read, write and count (up to 36) and knows the alphabet
  • Assessed in Amiens University Memory Clinic for:
  • Mild severity impairment (MMSE> 19) or major severity impairment related to:
  • AD according to Albert criteria and McKhann criteria
  • DCL according to McKeith criteria
  • FTLD according to Rascovsky criteria
  • CBD according to Armstrong's criteria
  • PSP according to Höglinger criteria
  • For Stroke PATIENTS
  • informed consent
  • Patients between 40 and 85 years old,
  • French native language,
  • Social Security affiliation,
  • Can read, write and count (up to 36) and knows the alphabet
  • Having suffered a stroke, hospitalized in neurology, visualized by imaging

Exclusion criteria

  • Mental retardation or guardianship
  • Other current or past brain condition affecting cognition, including:
  • Severe head trauma
  • Epilepsy prior to stroke still requiring previous treatment
  • Parkinson disease, multiple sclerosis
  • Brain tumor or brain radiation therapy
  • Current or past schizophrenia or psychosis
  • Active or past psychiatric impairments requiring a stay> 2 days in a specialized environment
  • Contra indication to MRI
  • Comorbidity with life expectancy <1 year
  • Comorbidity affecting cognition in particular:
  • Alcohol (> 3 glasses / day) or history of alcohol withdrawal syndrome
  • Opiate or cocaine addiction or opiate withdrawal syndrome
  • Renal failure (dialysis or creatinine clearance <30)
  • Hepatic failure (spontaneous INR> 1.5 or PT <60%)
  • Respiratory failure requiring oxygen therapy
  • Heart failure (orthopnea> 2 pillows)
  • Persistent vigilance disorder (NIHSS1a score ≤1)
  • Cancer with paraneoplastic syndrome
  • Treatment with gold salts, D Penicillamine or other treatment with cognitive effect
  • Patient under guardianship or curators or private under public law
  • Pregnant and / or lactating woman

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

France · 1 center
  • CHU Amiens — Amiens

Identifiers

NCT: NCT05875103 · PI2022_843_0150

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗